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Coordination of the immune response to viral infection and disease in the brain is believed to involve bidirectional
interaction between the immune system and the central nervous system (CNS). Progressive multifocal leukoencephalopathy
(PML) is a demyelinating disease of the CNS that generally affects patients exhibiting an immunocompromised condition
due to various illnesses. The human polyomavirus, JCV, which infects greater than 70% of the adult population is the
etiological agent of this disease. Infection with JCV occurs during childhood and the virus remains in the latent state with
no apparent clinical signals. However, under immunocompromised conditions, the virus enters the lytic cycle, and upon
cytolytic destruction of glial cells, causes PML. To understand the molecular mechanism underlying immune regulation of
JCV replication, we have developed a cell culture system and have investigated the effect of soluble factors from T-cell
cultures on replication of JCV DNA in glial cells. Our data demonstrate that replication of JCV DNA in the presence of PMA-
stimulated T-cell supernatant is substantially decreased in transfected glial cells. Heat-inactivation and size-fractionation
studies revealed participation of a heat labile factor(s) which loses its maximum activity at 607 and ranges between 30 and
100 kDa in size. The unfractionated T-cell supernatant and the fraction enriched in 30- to 100-kDa proteins reduced the
level of viral DNA replication during the early phase of the lytic cycle. These observations suggest that regulatory factors
which are secreted by immune cells may modulate the level of JCV DNA replication in glial cells. The importance of these
observations in reactivation of JCV in immunocompromised individuals and development of PML is discussed. q 1996
Academic Press, Inc.
JCV from a latent state (3). Thus, it is likely that the im-Infection with the human papovavirus, JCV, is a com-
mune system of healthy individuals retains the virus inmon event, which occurs during childhood. Sero–epide-
the latent state and that alterations in immune systemmiological studies have indicated that between 70 and
function could facilitate reactivation of viral gene expres-90% of the human population is exposed to JCV by 17
sion and guide the virus from a latent to a lytic phase.years of age and exhibits no symptoms of clinical dis-
During the past 8 years, many efforts have been cen-ease that could be attributed to JCV. However, in immu-
tered on the determination of the regulatory mechanismsnosuppressed middle-aged and elderly patients with
which restrict expression of the JCV genome in glial cells.lymphoproliferative disease, in AIDS patients of all ages,
Examination of the JCV regulatory region by transientand in individuals undergoing immunosuppressive thera-
transfection of glial and nonglial cells (5–8) and in vitropies, JCV causes a demyelinating disease of the central
transcription (9, 10) has led us to believe that a highlynervous system (CNS) named progressive multifocal leu-
complicated regulatory mechanism which includes par-koencephalopathy (PML) (for review see 1–3). The histo-
ticipation of several inducible factors determines glial-pathology of lesions from PML-affected brains suggests
specific expression of the viral genome (11–14). Whetherthat demyelination results from the lysis of oligodendro-
the levels of expression and/or activity of the participat-cytes, the myelin-producing glial cells of the CNS (4).
ing factors are altered by the immune status of the indi-Since the development of PML in patients who were
viduals remains to be investigated. Another level of regu-known to be seropositive long before clinical manifesta-
lation which restricts replication of JC virus in glial cellstion is not associated with the increase in JCV-specific
rests on the ability of the virus-containing cells to accom-IgM antibody titer during the course of the disease, there-
modate efficient replication of viral DNA. Similar to thefore, it is assumed that PML arises from reactivation of
other papovaviruses, replication of JCV DNA requires, in
addition to the viral early gene product, T-antigen, a se-
ries of replication factors, and DNA polymerase from the1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (215) 923-5905. host (15). Thus, expression and activity of these regula-
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FIG. 1. Suppressive effect of activated T-cell factors on JCV replication. T-cell-enriched nylon wool nonadherent cells from a healthy, normal
individual were incubated at 2 1 106 cells/ml in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) in the
absence or presence of PMA (25 ng/ml) plus ionomycin (175 ng/ml). After 1 hr, cells were washed and cultured under the same conditions, but
with no PMA or ionomycin for 24 hr. Two milliliters of test supernatants either directly or after dilution in DMEM was added to the transfected U-
87MG glial cells. After 12 hr, cells were washed with PBS and maintained in DMEM plus 10% FCS. Transfection was carried out by the Ca phosphate
precipitation method (20) utilizing 2 mg of the construct encompassing the JCV control region and the origin of DNA replication (pJCV-CAT) and 8
mg of the T-antigen-producing plasmid (pCMV-T). DNA and protein extracts from independent groups were made at 72 hr posttransfection. Low-
molecular-weight DNA was digested with BamHI and DpnI, electrophoresed on a 1% agarose gel, transferred to a nytran membrane, and hybridized
with a pJCV-CAT 32P-labeled probe. (A) Resultant Southern blot illustrating replicated JCV DNA (shown by the arrow). Lane 1, U-87MG cells transfected
with pJCV-CAT in the absence of pCMV-T; lanes 2–6, U-87MG cells cotransfected with pJCV-CAT and pCMV-T in the absence (lane 2) or in the
presence of 20% (lane 3) and 50% (lane 4) of stimulated T-cell supernatant. Lanes 5 and 6 indicate the level of JCV DNA replication in glial cells
maintained in the presence of 20% (lane 5) or 50% (lane 6) of unstimulated T-cell supernatant. (B) Quantitation of the JCV DNA levels in A using a
PhosphorImager. (C) Western blot analysis of 20 mg of nuclear proteins from the transfected U-87MG glial cells cultured in the presence or absence
of T-cell supernatants using anti-T-antigen antibody (PAb416) upon detection by alkaline phosphatase. Lane 1, control baculovirus-produced SV40
T-antigen; lane 2, untransfected glial cells; lane 3, glial cells transfected with 10 mg of JCV T-antigen-producing plasmid (pCMV-T) with no treatment;
lane 4, glial cells transfected with 10 mg of T-antigen-producing plasmid maintained in media supplemented with 20% unstimulated supernatant;
and lanes 5 and 6, transfected glial cells maintained in media containing 20 and 50% of stimulated supernatant. Similar results have been obtained
in three replicate experiments.
tory proteins could also influence the level of viral DNA supernatant. To examine the effect of conditioned media
on JCV DNA replication, the human glial cell line U-87MGreplication in the cells.
In this respect, one could envision a model in which was cotransfected with a replication-competent plasmid
containing the JCV control region including the origin ofthe immune system retains the virus in the latent state by
interfering with expression and/or activity of the cellular DNA replication (pJCV-CAT) and a plasmid expressing
JCV T-antigen (pCMV-T). The transfected cells wereproteins which have control over viral DNA replication.
To examine the potential mechanism for involvement of grown in Dulbecco’s modified Eagle medium (DMEM)
in the absence or presence of increasing amounts ofthe immune system in JCV DNA replication independent
from its influence on the viral gene expression, we de- conditioned media derived from PMA-stimulated or the
control unstimulated human T-lymphocytes. After 72 hr,signed a series of transfection and infection experiments
in glial cells. Our results indicate that the supernatant low-molecular-weight DNAs were prepared by the Hirt
procedure (17), and after treatment with DpnI, whichfrom activated T-cells contains soluble factors which de-
crease the level of DNA replication in transfected and cleaves away the input plasmid DNAs, the replicated
DNAs were digested with BamHI and analyzed by South-infected human glial cell lines.
In the first series of studies, we examined the effect ern blot technique (18). Results shown in Fig. 1A indicate
that production of JCV T-antigen from pCMV-T stimulatesof secreted factor(s) from T-lymphocytes on replication of
JCV DNA in glial cells. To obtain T-cell secretory factors, replication of the JCV DNA and that the factors present
in the conditioned media from PMA-stimulated T-cellsnormal T-cells were prepared by incubating peripheral
blood mononuclear cells on nylon wool columns (16). (CMs) decreased the level of viral DNA replication in glial
cells (compare lane 2 to lanes 3 and 4). Under similarThe nylon nonadherent cell populations obtained were
depleted of B-cells (1–4% CD19 positive) and enriched conditions, the supernatant from unstimulated T cells
(CMu) showed a minimal inhibitory effect on the viralin T-cells (81–86% CD3/) with the balance (10–18%) be-
ing NK cells and approximately 0.1 to 0.4% CD14/ mono- DNA replication (Fig. 1A, compare lane 2 to lanes 5 and
6). The decrease in the level of JCV DNA replication maycytes. This T-cell-enriched population was stimulated
with PMA and ionomycin for 1 hr prior to culture, washed, not be attributed to the decline in the level of JCV T-
antigen in the cells, since under the same conditions,and then cultured for 24 hr prior to harvesting culture
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FIG. 2. Heat inactivation of T-cell conditioned media. Supernatants from PMA / ionomycin-stimulated T-cells were treated for 2 hr at 37, 60, 75,
and 907. The heat-treated supernatants were diluted to 33% with 2 volumes of DMEM and added to U-87MG (A) and SVG (B) cell culture dishes
which had been transfected with 3 mg of JCV reporter plasmid in the absence or presence of 10 mg of T-antigen-producing plasmid, respectively.
After 72 hr, low-molecular-weight DNA was extracted, and after digestion with SacI and DpnI, analyzed by Southern blot. The arrows depict the
position of two DNA fragments produced upon SacI digestion of the replicated JCV DNA. In B, lane 1 indicates samples from untransfected SVG
cells. Percentage suppression was determined by PhosphorImager analysis of the bands shown by the arrows.
the level of this protein as examined by Western blot any circumstances, the results from both cells clearly
indicate that T-cell-enriched supernatant has negativeanalysis in the transfected cells remained unchanged.
Figure 1C illustrates results from Western blot analysis regulatory effect on the viral DNA replication.
In a second series of studies, the proteins present infor detection of T-antigen in transfected cells with no
treatment (lane 3), after treatment with unstimulated (lane the supernatants were size-fractionated into three frac-
tions ranging between 0 and 10, 10 and 30, and 30 and4), or with stimulated T-cell supernatant (lanes 5 and 6).
As evident from the intensity of the band corresponding 100 kDa. Results from DpnI analysis of DNA obtained
from the transfected glial cells maintained in the pres-to T-antigen, treatment of cells with T-cell supernatant
exhibits no effect on the level of T-antigen production in ence of these fractions are shown in Fig. 3. As seen in
Fig. 3A, the greatest level of suppression of JCV DNAthese cells. Perhaps, it should also be mentioned that
treatment of cells with the PMA-treated T-cell superna- replication was observed in the glial cell culture which
was supplemented with fractions containing moleculestant showed no effect on cell viability as examined by
Trypan blue assay (data not shown). greater than 30 kDa. Figure 3B summarizes the results
of two independent experiments.To gain insight into the nature of the inhibitory soluble
factor(s) present in the supernatant from activated T-lym- Taken together, these data suggest that the T-cell su-
pernatant contains a heat labile factor(s) with an appar-phocytes, the supernatant was heat-treated for 2 hr at
37, 60, 75, and 907 prior to addition to the media of the ent molecular weight greater than 30 kDa in size with
the ability to suppress replication of JCV DNA in glialtransfected cells. As shown in Fig. 2A, exposure of the
supernatant to 607 decreased the level of suppression cells.
Next, we determined the effect of the activated T-cellwrought by the supernatant. In addition to U-87MG cells,
replication of JCV DNA was also inhibited in SVG cells, supernatant on JCV replication during the course of lytic
infection. In this study, SVG cells were infected with thea human fetal glial cell line which continuously produces
SV40 T-antigen (19), by the supernatant from activated Mad-4 strain of JC virus for 2 hr after which the cells
were washed and incubated with fresh media containingT-lymphocytes (Fig. 2B, compare lane 2 to lane 3). We
noticed that the level of suppression in SVG cells was unstimulated or stimulated T-cell supernatants. After 12
hr the cell culture medium was replaced by fresh DMEMmore dramatic and that exposure of the supernatant to
607 for 30 min completely abrogated the level of suppres- plus fetal calf serum. At 6, 8, and 10 days postinfection,
low-molecular-weight viral DNAs were prepared andsion of JCV DNA replication by the activated T-cell super-
natant in these cells (Fig. 2B, compare lane 3 to lane 4). after cleavage with BamHI, the linearized viral DNA was
analyzed by Southern blot. As shown in Fig. 4, treatmentWhether or not the observed variations in the extent of
suppression by T-cell supernatant in these two cell lines of cells with stimulated supernatant decreased the levels
of viral DNA replication at 6 days postinfection. Quantita-is attributed to the nature of the cells and/or the source
of T-antigen (exogenous vs endogenous) remains un- tive comparison of the intensity of the band correspond-
ing to the viral DNA obtained from cells treated withclear. It should also be noted that the level of endoge-
nous T-antigen produced in SVG cells remained un- unstimulated and stimulated conditioned media indi-
cated approximately 63% suppression of viral DNA repli-changed upon the treatment (data not shown). Under
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FIG. 3. Size fractionation of the T-cell supernatant. T-cell supernatant diluted to 33% with DMEM was size fractionated by Centriprep Columns
(Amicon) and the three fractions enriched in molecules ranging between 0 and 10, 10 and 30, and 30 and 100 kDa were collected. Two milliliters
of unfractionated crude and various fractions were added to the transfected U-87MG cells as described in the legend to Fig. 2. (A) Position of newly
replicated JCV DNA in glial cells after SacI digestion is shown by the arrows. (B) Quantitative analysis of JCV DNA replication obtained from glial
cells treated with crude (unfractionated) T-cell supernatant and the various fractions. These results represent the average of two independent
experiments.
cation by the activated supernatant (Fig. 4B). This value
was decreased to 33.3 and 41.2 after 8 and 10 days,
respectively. This observation suggests that the soluble
factor(s) present in the activated supernatant is capable
of reducing the level of viral DNA replication at the early
phase of DNA replication. However, as the copy number
of the viral genome began to increase, the inhibitory
effect of the T-cell supernatant on viral replication is less
detectable. As shown in Fig. 4C the level of endogenous
T-antigen in SVG cells during the course of these studies
remains unchanged, indicating that the decrease in the
level of JCV DNA replication may not be attributed to the
action of T-antigen.
In the last series of studies, we utilized size-fraction-
FIG. 4. Effect of conditioned media on JCV DNA replication during ated stimulated T-cell supernatant to determine the ap-
the course of infection. (A) Human fetal glial cells (SVG) were either proximate molecular mass of the component which af-
mock-infected (lane 1) or infected with approximately 100 hemaggluti- fects JCV DNA replication during the infection cycle.
nin units of the Mad-4 strain of JCV (lanes 2–7) according to the method
Again, after infection of SVG with the Mad-4 strain ofdescribed previously (21). Five milliliters of 33% diluted test superna-
JCV, cells were maintained in media supplemented withtants from unstimulated (U) and stimulated (S) T cells was added, as
described in the legend to Fig. 2, to JCV-infected cell culture plated fractions containing 0- to 10-kDa, 10- to 30-kDa, and
with 1.0, 0.5, or 0.25 million SVG cells in 100-mm dishes for a 6-, 8-, greater than 30-kDa (30- to 100-kDa) molecules. Analysis
or 10-day infection period, respectively. In indicated days postinfection, of viral DNA replication after 6 days postinfection indi-
low-molecular-weight DNA was prepared and, following digestion with
cated that in accordance with our transfection studies,BamHI, analyzed by Southern blot technique. (B) Quantitative analysis
the fractions containing the molecules greater than 30of the JCV DNA bands in A using a PhosphorImager. The values repre-
sent percentage suppression of viral DNA replication in glial cells kDa exhibit more inhibitory action on replication of the
grown in the presence of stimulated vs unstimulated T-cell conditioned viral genome (Fig. 5). Furthermore, results from heat-inac-
media. (C) Western blot of 20 mg of whole cell extract from a duplicate tivation studies indicated that incubation of the activated
experiment as in A was analyzed for the presence of SV40 or JCV T-
supernatant at 607 for 30 min substantially decreased itsantigen with anti-T-antigen antibody PAb416 and detected by alkaline
ability to block replication of JCV during the infectionphosphatase. M is protein high-molecular-weight marker depicting po-
sitions of 98- and 68-kDa bands. cycle (data not shown).
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FIG. 5. Effect of size-fractionated conditioned media from T-cells on replication of JCV DNA during the course of infection. Approximately 2.5 1
105 SVG cells were mock-infected (lane 1) or infected with JCV (lanes 2–6) as described in the legend to Fig. 4. Cells were either nontreated (lane
2) or treated with 5 ml of unfractionated crude (lane 3) or size-fractionated T-cell supernatants (lanes 4–6) for 12 hr. (A) Analysis of viral DNA
replication by Southern blot technique. (B) Western blot analysis of T-antigen production in the JCV-infected SVG cells during the course of infection.
Lanes 1 in A and B represent analysis of DNA and protein, respectively, from uninfected SVG cells. M is protein high-molecular-weight marker
depicting positions of 98-, 68-, and 43-kDa protein species.
These results suggest that molecules with similar nario appropriately correlates with the development of
PML in immunosuppressed individuals whose immunecharacteristics suppress viral DNA replication in
transfected cells and down-regulate JCV DNA replication cells are not fully functional. It has been postulated that
the human polyomavirus JCV, which infects a large por-during the course of infection. These observations, on
the possible role of regulatory factors from immune cells tion of the human population, remains at latency as long
as the immune cells are healthy and functional. However,in controlling JCV replication in glial cells, set the stage
for launching comprehensive biochemical studies which under conditions where the immune system is compro-
mised, JCV escapes from the latent phase and, uponinclude large-scale purification of the participant pro-
tein(s) and identification of the immune-cell-derived sup- replication in glial cells, induces PML in the affected
individuals.pressor factor.
Of note, we also evaluated the effect of conditioned Based on these observations, we examined the ability
of a secreted factor(s) from T-cells in regulating JCV DNAmedia derived from PMA-treated U-87MG glial cells on
replication of JCV DNA. Our results indicated that the replication. Our results reveal the involvement of a mole-
cule(s) derived from T-cells in regulation of JCV DNAsupernatants from glial cells treated with PMA for 12, 24,
and 36 hr exert no inhibitory effect on the level of JCV replication. Evidently the apparent molecular mass of the
factor(s) that is greater than 30 kDa distinguishes it fromDNA replication in the transfected glial cells. Thus, it
appears that unlike T-cells, treatment of glial cells with the previously characterized small immunomodulators
and cytokines. Accordingly, our recent studies utilizingPMA does not induce secretion of the suppressor with
the ability to influence JCV DNA replication. Moreover, we highly purified cytokines such as IL-2, TGFb, and TNFa
implied that these factors in a single combination mayexamined the ability of the activated T-cell supernatant to
induce a secretory factor from U-87MG cells that may in not be as effective in regulating replication of JCV DNA.
Moreover, inclusion of antibodies against TGFb andturn affect replication of JCV DNA in the transfected cells.
Again, our data showed that the level of JCV DNA replica- TNFa in T-cell supernatant culture suggested that these
cytokines may not be responsible for T-cell-mediatedtion remains virtually unaffected upon treatment of the
transfected cells with supernatant from U-87MG cells suppression of JCV DNA in glial cells. The nature of this
regulator(s) with the capacity to suppress JCV DNA repli-activated with T-cell supernatant.
It is well-established that cross-communication be- cation and the mechanism of its action on viral DNA
replication remain unclear at present.tween the immune system and the central nervous sys-
tem plays an important role in the pathogenesis of a Our studies have indicated that treatment of glial cells
with PMA as well as with several immunomodulatorsbroad spectrum of CNS diseases caused by cerebral
trauma, tumors, degeneration, and viral infections. It is including IFNg and TNFa induces expression of an 80-
kDa binding protein, termed GBPi, that interacts with thebelieved that altered levels of several inflammatory medi-
ators, immunomodulators, and cytokines affect the deli- sequences spanning the origin of viral DNA replication
(14). Similarly, treatment of glial cells with T-cell superna-cately balanced interaction of the immune system and
the central nervous system. Hence, deregulation of the tant induced expression of a protein in glial cells which
exhibited binding characteristics similar to those of GBPiimmunomodulators and other important cellular genes
could have a major impact upon neural cell function. (Raj et al., unpublished observations). Studies are cur-
rently in progress to assess the importance of the GBPiIn addition, such an alteration could affect the state of
pathogenic viruses which remain in latency during non- in the observed suppression of the viral DNA replication
by T-cells in glial cells. It should also be mentioned thatimmunosuppressed conditions. Evidently, such a sce-
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